|
|
| ÁÍ¡.440 | 4 |  | 4.00 |
| »ÃСÒÈ¡ÃзÃǧÊÒ¸ÒóÊØ¢ ©ºÑº·Õè106 | 3 | | 3.00 |
| salicylic acid ÊÒáѹÃÒ | 3 | | 3.00 |
| âäÍب¨ÒÃÐÃèǧ 0-5 »Õ full text | 3 | | 3.00 |
| Çѳâä adr fulltext | 3 | | 3.00 |
| ¹ÔÊÔ§àË ËÁÍÁÕ »ÃШÓà´×͹äÁèÁÒ | 3 | | 3.00 |
| ÂÒµéÒ¹Çѳâä full text | 2 | | 2.00 |
| ¢éͤÇÃÃÐÇѧ¢Í§¡ÒÃãªéÂÒnahco3 | 2 | | 2.00 |
| ʶҺѹâä¼ÔÇ˹ѧ »Ò¹á´§ | 2 | | 2.00 |
| ÁÒµÃÒ°Ò¹¡ÒþÂÒºÒÅâäÍب¨ÒÃÐÃèǧã¹à´ç¡ | 2 | | 2.00 |
| ¢Õé¼Ö駻éÒÂµÒ | 2 | | 2.00 |
| ÊÒ¸ÒóÊØ¢ ¡ÅÙµÒä¸â͹ | 2 | | 2.00 |
| ÊÒÃà¨×Í»¹ÍÒËÒà fda | 2 | | 2.00 |
| ¡ÒõÃǨ¤ÇÒÁ¨ØÎÒÃì´´ÔÊ | 2 | | 2.00 |
| ºÃÔºÒÅ dilantin | 2 | | 2.00 |
| ͧØè¹ ¿ÍÁÒÅÕ¹ | 2 | | 2.00 |
| usp di.: approved drug products and legal requirements volume 3 | 2 | | 2.00 |
| ¹éÓáÃè | 2 | | 2.00 |
| ¾.Ã.º.à¤Ã×èͧÁ×Íá¾·Âì ¾.È.2551 | 2 | | 2.00 |
| »ÃСÒÈ¡ÃзÃǧÊÒ¸ÒóÊØ¢ ©ºÑº104 | 1 | | 1.00 |
| ËÅѡࡳ±ìÇÔ¸Õ¡Ò÷Õè´Õ㹡ÒüÅÔµÂÒ á¼¹»Ñ¨¨ØºÑ¹ | 1 | | 1.00 |
| Ä·¸Ôì¢Í§ÂÒâ«áÅ Á | 1 | | 1.00 |
| ÂÒʵÃÕà¾çÀÒ¤ ᤻«ÙÅ ¡Ô¹áÅéÇá·é§ | 1 | | 1.00 |
| ¨ÃÔ§ã¨ÂÍ´ | 1 | | 1.00 |
| ¡ÅØèÁ¤Çº¤ØÁà¤Ã×èͧÊíÒÍÒ§ | 1 | | 1.00 |
| ÇêԵ ÊÁà¾ÃÒÐ | 1 | | 1.00 |
| á¼¹·Õè ÈÙ¹Âìà¡Ô´ãËÁè (ËÔ§) | 1 | | 1.00 |
| âŪÑè¹ÊÁعä¾Ã»éͧ¡Ñ¹áʧᴴ á¾¹-ÇÕ | 1 | | 1.00 |
| sulforaphane mahidol | 1 | | 1.00 |
| ÀÒ¾¹Ò»ÒÊ¡ÑÅ ÅÒÁÕ | 1 | | 1.00 |
| àÍç¹ÃÃéÍÂËÇÒ¢Ҵ | 1 | | 1.00 |
| àÍ¡ÊÒÃÊÃØ»¡ÒúÃÃÂÒÂÃкҴÇÔ·ÂÒ | 1 | | 1.00 |
| Í ¡ÒÃÊÑÁÁ¹ÒàÃ×èͧ gmp ÂÒá¼¹»Ñ¨¨ØºÑ¹ | 1 | | 1.00 |
| ¹ÒÂá¾·ÂìÇÔâè¹ì ÈÃÕÍØÌÒþ§Èì | 1 | | 1.00 |
| ÂÒ㹡ÅØèÁູâ«ä´ÍÒ«Õ¿Õ¹ | 1 | | 1.00 |
| ÇÔ¸Õ¡ÒÃãªéËéͧÊÁØ´ | 1 | | 1.00 |
| ¤ÅѧàǪÀѳ±ì full text | 1 | | 1.00 |
| §Ò¹ÇÔ¨ÑÂÂÒÅ´¤ÇÒÁÍéǹ | 1 | | 1.00 |
| ÃÒ¤Ò¡Òéմ⺷ÙÅÔ¹ÑèÁ ·çÍ¡«Ô¹ÃÑ¡ÉÒ ´ÕÊâ·à¹Õ | 1 | | 1.00 |
| ÇԹѠ´ÐËìÅѹ ¼ÅÔµÀѳ±ìàÊÃÔÁÍÒËÒà | 1 | | 1.00 |
| âç§Ò¹¼ÅÔµ¹éÓá¢ç§ | 1 | | 1.00 |
| ¤ÇÒÁ¨Ø ÎÒÃì´´ÔÊ | 1 | | 1.00 |
| ¾ÔÃÁÅ à·¾Á§¤Å | 1 | | 1.00 |
| ÍÁà ¹¹·Êص 2525 ºÃóҹءÃÁ | 1 | | 1.00 |
| ʶҹ¡ÒóìÇѳâäã¹ÀÒ¤µÐÇѹÍÍ¡à©Õ§à˹×ͧ͢»ÃÐà·Èä·Â »Õ 2552 | 1 | | 1.00 |
| tgn1412 trial | 1 | | 1.00 |
| ¨Ó˹èÒÂÂÒŴ˹éÒ·éͧ¢Í§âç¾ÂÒºÒŨØÌÒ | 1 | | 1.00 |
| àºâ·â«¹¤ÃÕÁ | 1 | | 1.00 |
| librium haldol | 1 | | 1.00 |
| äÍ»Ãͷ㹤ÅÔ¹Ô¡·Ñ¹µ¡ÃÃÁ | 1 | | 1.00 |
| ÂÒá¡éä¢éËÇÑ´ | 1 | | 1.00 |
| ʶҺѹâä¼ÔÇ˹ѧàÅà«ÍÃì¡Ó¨Ñ´ä½áÅлҹ | 1 | | 1.00 |
| «Ø¤ÃÒâÅÊ Í | 1 | | 1.00 |
| µÒÃÒ§¡ÒÃãªéÇѵ¶Øà¨×Í»¹ÍÒËÒà | 1 | | 1.00 |
| sop¡ÒüÅÔµ¹éÓ¾ÃÔ¡à¼Ò | 1 | | 1.00 |
| ºÃÔÉÑ· ÂÔ¹´Õ à¹à¨ÍÃì â»Ã´Ñ¡Êì ¨íÒ¡Ñ´ | 1 | | 1.00 |
| ÃéÒ¹ÂÒÊÒÁÑ âç¾ÂÒºÒÅÈÔÃÔÃÒª | 1 | | 1.00 |
| ÃÑ¡ªÒµÔ ÈÔÃԪѠ| 1 | | 1.00 |
| ºÃÔÉÑ·ÂÔ¹´Õ à¹à¨ÍÃì â»Ã´Ñ¡Êì ¨Ó¡Ñ´ | 1 | | 1.00 |
| â´ÁÔ¤ØÁµÒÂä´é | 1 | | 1.00 |
,
User's Guide
˹éÒÅçÍ¡ÍÔ¹| ʶԵÔÃÒ»Õ
| ʶԵÔÃÒÂà´×͹
| ʶԵÔÃÒÂÇѹ
| ʶԵÔÃÒªÑèÇâÁ§
| Eng
Pageview 
Unique IPs 
Sessions